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Abstract
Glycosylation of proteins, lipids and proteoglycans in human cells involves at least 167 identified
glycosyltransferases (GTfs), and these orchestrate the biosynthesis of diverse types of glycocon-
jugates and glycan structures. Mutations in this part of the genome—the GTf-genome—cause
more than 58 rare, monogenic congenital disorders of glycosylation (CDGs). They are also statis-
tically associated with a large number of complex phenotypes, diseases or predispositions to com-
plex diseases based on Genome-Wide Association Studies (GWAS). CDGs are extremely rare and
often with severe medical consequences. In contrast, GWAS are likely to identify more common
genetic variations and generally involve less severe and distinct traits. We recently confirmed that
structural defects in GTf genes are extremely rare, which seemed at odds with the large number
of GWAS pointing to GTf-genes. To resolve this issue, we surveyed the GTf-genome for reported
CDGs and GWAS candidates; we found little overlap between the two groups of genes. Moreover,
GTf-genes implicated by CDG or GWAS appear to constitute different classes with respect to their:
(i) predicted roles in glycosylation pathways; (ii) potential for partial redundancy by closely hom-
ologous genes; and (iii) transcriptional regulation as evaluated by RNAseq data. Our analysis sug-
gest that more complex traits are caused by dysregulation rather than structural deficiency of
GTfs, which suggests that some glycosylation reactions may be predicted to be under tight regula-
tion for fine-tuning of important biological functions.
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Introduction
Glycosylation of proteins, lipids and proteoglycans (glycoconjug-
ates) in mammalian cells is directed by a large number of glycosyl-
transferases that each serve unique functions in building the diverse
set of glycan structures produced—designated the glycome
(Cummings 2009; Hansen et al. 2015). A subset of glycosyltrans-
ferases (GTfs) can be grouped into a set of enzymes that are
involved in initiating glycoconjugates, usually catalyzing the first
attachment of a monosaccharide to a protein backbone or lipids. An
exception to this activity is found with the oligosaccharyltransferase
complex, that initiates N-glycosylation of proteins by transferring a
preformed oligosaccharide. The initiation step is followed by groups
of enzymes that elongate, branch and cap growing oligosaccharides
on glycoconjugates. The human genome contains over 214 GTf-
genes (Hansen et al. 2015), of which 167 can be predicted to direct
fairly specific biosynthetic steps in glycosylation pathways of pro-
teins, lipids and proteoglycans as illustrated in Figure 1 (Narimatsu
et al. 2018).
Glycans serve important functions in essentially all biological
processes in a cell and organism (Varki 2017), and genetic deficien-
cies in GTf-genes and glycosylation capacities have been shown to
cause/underlie over 58 rare congenital disorders of glycosylation
(CDGs) (Table I) (for reviews see Freeze et al. 2014; Jaeken and
Péanne 2017). Most of these CDGs have so far been found to be in
the N-glycosylation pathway (Freeze et al. 2014), the O-Man glyco-
sylation pathway directed by the POMT1/T2 genes (Sheikh et al.
2017), and the proteoglycan glycosylation pathway (Mizumoto
et al. 2014), although deficiencies in the GPI-anchor assembly
(Freeze et al. 2015; Ng and Freeze 2015) and other types of
O-glycosylation have also emerged (Jaeken and Péanne 2017). Most
of the identified CDGs to date are caused by severe deficiencies in GTf
functions as result of structural defects in the coding regions and/or
splicing, and with global effects on the glycosylation capacity and
resulting glycan structures. However, CDGs caused by more subtle
glycosylation deficiencies are emerging with GTf genes that are
members of large homologous gene families, where paralogs may
provide partial compensation. The most illuminating examples are
members of the large polypeptide GalNAc-transferase (GALNT2
and 3) gene family (GT27) (Kato et al. 2006; Khetarpal et al. 2016),
the β4Gal-transferase family (GT7) (B4GALT1) (Hansske et al.
2002), and the large sialyltransferase family (GT29) (ST3GAL3 and
5) (Hu et al. 2011; Edvardson et al. 2013; Simpson et al. 2004),
where deficiencies in individual genes are predicted to lead to subtle
partial losses of glycosites or glycan structures that only affect a sub-
set of glycoconjugates and/or specific cell types.
Deleterious single-nucleotide variants (SNVs) in GTf-genes are
rarely found in whole exome sequencing (WES) of different popula-
tions, which we recently confirmed by analysis of deep WES data
from 2000 Danes (Hansen et al. 2015). In this study, we only identi-
fied a few alleles with known disease-causing SNVs from
POMGNT1, ALG1, ALG6 and ALG12. Interestingly though, we
did identify two less rare deleterious SNVs in 2 out of the 20
GALNT genes (GALNT5 and T14) initiating O-GalNAc-
glycosylation, although the role of these SNVs are still unknown.
However, Genome-Wide Association Studies (GWAS) increas-
ingly associate a large number (~98) of the human GTf-genes with
different complex traits or predisposition to diseases (Table I). While
GWAS candidates clearly require validation, a cursory survey of the
literature suggested that most of the implicated GTf-genes were dif-
ferent from the classical group of identified CDG genes. Many
GWAS candidate GTf-genes are members of large homologous gene
families (such as GT10, GT27, GT29 and GT31) with poorly char-
acterized nonredundant functions (see Supplementary data
Table SIV for references), and with potential for functional overlap
by isoenzymes. This redundancy may cloud our understanding of
the nonredundant functions of individual enzymes, rendering it
extremely difficult to rationally predict how these genes may be
implicated in the particular candidate GWA traits. We hypothesize
that this partly explains the lack of attention to the potential signifi-
cance of GTfs in more common complex traits or disease conditions.
Recently, we therefore pursued one of the most substantiated
GWAS candidate genes, GALNT2, with a GWAS predicted role in
regulating high-density lipoprotein (HDL) and triacylglycerol
(Kathiresan et al. 2008; Teslovich et al. 2010; Willer et al. 2013).
GALNT2 encodes one of a family of up to 20 polypeptide GalNAc-
transferase isoenzymes controlling initiation of GalNAc-type
(mucin-type) O-glycosylation (Bennett et al. 2012; Steentoft et al.
2013). We were able to confirm that loss of GALNT2 in fact does
cause reduced HDL in two very rare consanguineous cases of com-
plete deficiency of this gene, as well as in several animal models
(Khetarpal et al. 2016). In addition, we identified two GALNT2
isoform-specific protein substrates, ANGPTL3 and PLTP, for which
loss of glycosylation in both cases could affect HDL metabolism
(Schjoldager et al. 2012; Khetarpal et al. 2016). Importantly, how-
ever, the GWAS signal for GALNT2 and low HDL is located in the
first large intron of the gene close to a liver-specific regulatory elem-
ent, and several studies have demonstrated that the GWAS single
nucleotide polymorphism (SNP) signal induced allele-specific tran-
scription differences (Roman et al. 2015; Cavalli et al. 2016). Thus,
GALNT2 underlies a new rare CDG caused by complete loss-of-
function due to biallelic structural deficiency in the gene, and simul-
taneously GALNT2 is perhaps the first validated GWAS candidate
GTf-gene. Importantly, the molecular basis for the latter appears to
be organ-specific dysregulation of transcription rather than struc-
tural, and the phenotypic outcome remains altered HDL metabol-
ism. These findings suggest that GWAS point to a different group of
disorders of glycosylation caused by transcriptional dysregulation.
In the present study, we performed a systematic survey of GTf-
genes identified as CDG genes and those implicated as GWAS candi-
dates. This showed that GTf-genes associated with CDGs mainly
functioned in glycosylation reactions specific to a single glycosyla-
tion pathway, they were rarely part of close homologous families of
putative isoenzymes, and they were not predicted to exhibit substan-
tial organ-specific regulation. In striking contrast, GTf-genes impli-
cated as GWAS candidates often functioned in multiple
glycosylation pathways, and they were mainly members of isoen-
zyme families, and predicted to exhibit organ-specific regulation.
Our analysis suggests the existence of two distinct types of congeni-
tal glycosylation defects—one based on well-established and rare
structural gene defects (CDGs)—and one less well studied based on
regulatory gene effects (GWAS). Although the many GWAS candi-
date genes will require validation, we predict that this group points
to glycosylation features that require tight regulation to serve in
fine-tuning and specific co-regulation of protein functions.
Results
A global view of the GTf-genome
An assembly of the human GTf-genome was based on the CAZy
database annotation of GTfs (Lombard et al. 2014). Some 214
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Fig. 1. (A) Graphic rainbow depiction of predicted roles of the 167 human GTfs involved in glycosylation. Pathway-specific GTf-genes (114) serving the 15 distinct
glycosylation pathways are organized as vertical colored flows. Pathway-nonspecific GTf genes (53) serving elongation and capping are organized in horizontal
layers at the top. The glycosylation pathways are: GPI-anchor, glycolipids (two pathways), N-linked glycans, O-GalNAc mucin-type, O-Fuc type (two pathways),
O-GlcNAc type (EGF), O-Man type (POMT-directed), O-Man type (TMTC-directed), C-Man type, O-Glc type, O-Xyl type (proteoglycans), O-Gal type (collagen) and
O-GlcNAc type (cytosolic). GTf-genes directing the initiation and pathway determining steps are indicated at the bottom. For N-glycosylation the ALG1-14 GTf-genes
required for the preformed oligosaccharide (Glc3Man9GlcNAc2) are indicated as well. Six glycosylation pathways are directed by isoenzyme families with partial
functional redundancies including the GALNTs, POFUTs, TMTCs, DPY19Ls, XYLTs and COLGALTs. Partial redundancy is also found for the oligosaccharyltransferase
complex with the STT3A/B catalytic units (Ruiz-Canada et al. 2009). The assigned pathway-specific GTfs involved in core extension and elongation/branching (36)
are mainly unique without apparent close isoenzymes with overlapping functions. Exceptions include B4GALT5/T6 (LacCer glycolipid), GCNT1/T2/T4 (O-GalNAc),
LFNG/MFNG/RFNG (O-Fuc) and GXYLT1/T2 (O-Glc). The assigned pathway-nonspecific GTf-genes involved in elongation and capping are mainly members of large
isoenzyme families with considerable overlapping functions. While a number of studies have demonstrated preferences of, e.g. the many galactosyltransferase and
sialyltransferase isoenzymes for certain glycoconjugates and pathways, we chose here to consider these as pathway-nonspecific because conclusive evidence is still
missing (Tsuji et al. 1996, Amado et al. 1999; Togayachi et al. 2006). (B) Predicted transcriptional regulation of GTf-genes overlaid on the graphic depiction of GTf-
genes in panel (A). A heatmap scale for τ-values based on RNAseq organ expression data represent high (red) to low (blue) degree of regulation. (C) Known
CDG GTf-genes (red) and GWAS GTf-gene candidates (yellow) overlaid on the graphic depiction of GTf-genes in panel (A). Overlaps between CDG and
GWAS candidate GTf-genes are shown in orange. Glycan symbols are drawn according to the SNFG format (Varki et al. 2015).
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human GTf genes representing 48 CAZy GT-families have been
identified and their catalytic properties characterized to some detail
or their properties predicted based on close sequence similarity to
characterized genes (Hansen et al. 2015) (Supplementary data,
Tables SI and SII). We recently developed a graphical overview in
rainbow style of the 167 GTfs found in 44 out of the 48 GT-
families, that we can assign or predict to be involved in defined roles
in the biosynthesis of glycans, illustrating their predicted functions
in glycosylation pathways (Figure 1) (Narimatsu et al. 2018). An
elaboration upon the overview, providing more detailed assignment
of GTfs to specific glycan structures and glycosylation pathways can
be found in Figure 2. Currently, 15 distinct pathways of glycosyla-
tion can be defined including the glycophosphatidylinositol (GPI)
anchor, glycosphingolipid (Gal-Cer and Glc-Cer), N-linked glycan,
O-GalNAc mucin-type, O-Fuc type (POFUT1 and POFUT2 directed),
O-GlcNAc (EGF-specific), O-Man type (POMT-directed), O-Man
type (TMTC-directed), C-Man type, O-Glc type, O-Xyl type (proteo-
glycans), O-Gal type (collagen) and O-GlcNAc (cytosolic) pathways.
A group of 47 GTf-genes in 12 GT-families encode transferases
involved in other processes such as synthesis of hyaluronan or glyco-
gen, de-toxification of xenotoxins or endogenous compounds, as
well as genes with unknown functions. These are listed in Table I
and Supplementary data, Table SII as miscellaneous GTfs, and are
not considered in the analyses performed in this study. The current
assembly differs slightly from our previous GlyMAP report (Hansen
et al. 2015): MGAT4D, KDELC2 and A3GALT2, all not annotated
in CAZy, and the novel gene TMTC gene family (TMTC1-4, CAZy
GT105) recently identified as protein O-mannosyltransferases is
now included (Larsen et al. 2017). Furthermore, a group of genes
with proven GTf activity comprised of the ribitol-transferases FKRP
and FKTN (Kanagawa et al. 2016; Praissman et al. 2016) and the
Xyl-transferase TMEM5 (Manya et al. 2016) are included in
Figure 1 and Supplementary data, Table SI.
Assignment of GTf-genes to glycosylation pathways
As illustrated in Figures 1A and 2, GTf-genes can be classified
according their predicted functions in the 15 glycosylation pathways
recognized to date. A large proportion of the GTf-genome (114
genes) is predicted to encode for enzymes directing pathway-specific
glycosylation. These are mainly involved in the initiation step and
immediate core extension and/or branching of distinct types of glycocon-
jugates. In contrast, most genes controlling elongation and capping (53
genes) are predicted to be pathway-nonspecific and serve several dif-
ferent types of glycoconjugates (Figure 3A and Supplementary data,
Figure S1A).
Classification of GTf-genes into isoenzyme families
A total of 112 out of the 167 GTf-genes can be classified as being
members of paralogous gene families (Figure 3). Isoenzyme families
are found both in pathway-specific (62/114) and pathway-
nonspecific GTf-genes (50/53) (Table I and Supplementary data,
Figure S1B). Among the pathway-specific GTf-genes are the genes
involved in initiation of different types of O-glycosylation and
C-mannosylation including GALNT1-20 (GT27), TMTC1-4 (GT105),
DPY19L1-4 (GT98), XYLT1-2 (GT14) and COLGALT1-2 (GT25).
Among the pathway-nonspecific are the large gene families involved
in elongation (GT7, GT10, GT29 and GT31) and capping (GT10
and GT29) (Figure 1A). Although a number of studies suggest that
several isoenzymes in these GTf families may in fact function in spe-
cific glycosylation pathways, we have chosen to consider these as
pathway-nonspecific because conclusive evidence is still missing. The
most important examples are the sialyltransferases (GT29) specifically
serving the glycolipid (ST3GAL3/5, ST6GALNAC5/6 and ST8SIA1/
5) and the O-glycan (ST3GAL1 and ST6GALNAC1/2) pathways
(Tsuji et al. 1996).
Table I. Summary of the 167 human GTf genes characteristic’s found in Figure 1A
Glycan biosynthetic steps in
Figure 1A
Number of GTfs involved
in each stepd
Isoenzyme/
nonisoenzyme GTfse
Regulated/not-
regulated GTfsf
CDG-GTfsg GWA-GTfsh
Pathway-specific
GTfsa
Initiation step 58 36/22 26/32 27 25
Core extension step 33 10/23 14/19 15 15
Elongation and branching step 23 16/7 12/11 7 13
Total 114 62/52 52/62 49 53
Pathway-nonspecific
GTfsa
Elongation step 18 18/0 13/5 1 9
Capping step 35 32/3 32/3 2 18
Total 53 50/3 45/8 3 27
Total number of GTfs in Figure 1Ab 167 112/55 97/70 52 80
Miscellaneous GTfsc 47 – – 6 18
Total number of GTfs in the human genome 214 – – 58 98
aPathways-specific GTfs refers to Figure 1A lower part, pathway-nonspecific GTfs refers to Figure 1A upper part (elongation and capping). Details for the indi-
vidual GTfs can be found in Supplementary data, Table SI.
bFigure 1A includes a total of 167 GTfs represented by the pathway-specific and pathway-nonspecific GTf-genes; the number of isoenzymes/nonisoenzymes,
regulated/not-regulated CDG- and GWA-GTfs appear in this row.
cMiscellaneous GTf-genes include GTfs in the biosynthesis of hyaluronan and glycogen, GTfs involved in de-toxification or quality processes, and GTfs with
unknown function. These are not included in the text but details can be found in Supplementary data, Table SII.
dNumber of GTf-genes in the individual steps illustrated in Figure 1A.
eIsoenzymes include CAZy families or subfamilies of paralogous GTf-genes sharing sequence homology and overlapping enzymatic function; nonisoenzymes
include GTfs without human genome paralogs.
fRegulated and not-regulated GTfs represent GTfs with τ > 0.71 for regulated and τ≤0.71 for not-regulated genes, for details see Materials and methods and
Supplementary data, Table SVI.
gThe CDG GTf-genes are listed in Supplementary data, Table SIII.
hThe GWA GTf-genes are listed in Supplementary data, Table SIV.
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Global analysis of transcriptional regulation
of GTf-genes
Past studies of the expression of GTf-genes by traditional Northern
blot analysis, qPCR and immunohistochemistry have clearly demon-
strated that many of the GTf-genes are differentially regulated in tis-
sues and disease conditions, but a large fraction has also been
assigned more ubiquitous expression status. In order to probe the
GTf-genome more globally, we turned to the rapidly increasing vol-
ume of RNAseq data, and selected the Human Protein Atlas (HPA)
(Uhlén et al. 2015) RNAseq bodymap data as provided by the
EMBL-EBI Expression Atlas (Petryszak et al. 2016). As a first esti-
mate we grouped GTf-genes into regulated and not-regulated using
a defined τ-value (Yanai et al. 2005; Kryuchkova-Mostacci and
Robinson-Rechavi 2017) assigning a value between 0 and 1 for each
GTf-gene (Supplementary data, Table SVI). A threshold value was
chosen at τ > 0.71 for regulated and τ ≤ 0.71 for not-regulated GTfs
(Supplementary data, Figure S2). Using this cutoff we could classify
97/167 GTf-genes as regulated and 70/167 as being not-regulated
(Table I). In Figure 1B we overlaid τ-values as a heatmap on the graphic
view of glycosylation pathways. This revealed that GTf-genes respon-
sible for pathway-specific glycosylation were more often classified as
not-regulated compared to pathway-nonspecific genes (Supplementary
data, Figure S1C). Moreover, among the pathway-specific GTf-genes
those without paralogs such as those involved in the N-glycan pre-
cursor assembly and the immediate core extension of different types
of O-glycosylation, including the O-Man core M3 assembly and
the linker region for GAGs, were predominantly classified as not-
regulated. In contrast, the pathway-specific GTf-genes with paralogs
like the GALNTs directing O-GalNAc initiation, or those involved
in decision of branching in glycolipid, N-glycan and Heparan and
Chondroitin Sulfate glycosylation pathways were classified as regu-
lated. Among the pathway-nonspecific GTf-genes the group of
B4GALT1-4 (GT7) genes stand out as the only group classified as
not-regulated.
Miscellaneous
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GWASCDG
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Protein/lipid
GTfs
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2
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Pathway-specific
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CDG
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GWASA
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Fig. 3. Classification of the 167 human GTf-genes into (A) pathway-specific and pathway-nonspecific GTfs, (B) isoenzyme and nonisoenzyme GTfs, and (C) regu-
lated and not-regulated GTfs as represented in Table I. (A) The pathway-specific GTfs refers to genes in the initiation, core extension, or branching and elong-
ation steps (lower part of Figure 1A), and the pathway-nonspecific GTfs refer to genes in the elongation and capping steps (upper part Figure 1A). (B) The
isoenzyme GTfs refer to subfamilies of paralogous GTf genes with sequence homology and overlapping function; the nonisoenzymes GTfs refers to genes with-
out paralogs in the genome. (C) The regulated GTfs refer to genes (τ > 0.71) and not-regulated GTfs (τ < 0.71) refers to Figure 1B. For all three subdivisions of
the 167 GTf-genes, (A–C) the distribution of CDG and GWA GTf-genes as illustrated in Figure 1C is shown in the right column of pie-charts. Detailed information
for the individual GTf-genes are deposit in Supplementary data, Table SI.
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GTFs underlying CDGs and implicated by GWAS
represent distinct groups
More than 100 CDGs have been identified to date (Freeze et al.
2014; and 2015; Jaeken and Péanne 2017), and half of these (52)
are caused by partial or, rarely, as complete deficiencies in a GTf-
gene assigned to roles in the glycosylation pathways depicted in
Figure 1. Another six CDGs involve GTf-genes classified as miscel-
laneous (Table I and Supplementary data, Table SIII). We con-
sidered the 52 CDG GTf-genes and overlaid these on the graphic
view of glycosylation pathways in Figures 1C and 3. Interestingly,
the overlay pattern generated by CDG GTf-genes resembled the pat-
tern produced by not-regulated classified GTf-genes (Figure 1B). A
vast majority of the GTf-genes underlying CDGs (49/52) were classi-
fied as pathway-specific, and only three GTf-genes were classified as
pathway-nonspecific (ST3GAL3, ST3GAL5 and B4GALT1)
(Figure 3A). However, ST3GAL5—which has been associated with
infantile-onset epilepsy and a Salt and Pepper developmental regres-
sion syndrome—has been shown to selectively serve in the formation
of ganglioside GM3 glycolipids (Berselli et al. 2006). Moreover, a
smaller majority of the CDG GTf-genes (33/52) were classified as
being nonisoenzymes (Figure 3B), but only a quarter (13/52) as not
being regulated (Figure 3C).
We next surveyed the GWAS databases (primarily the GWAS
Catalog (MacArthur et al. 2017)) and literature for GWAS candi-
dates among the 167 GTf-genes with predicted roles in the glycosy-
lation pathways. We applied the following criteria for including
GWA GTf-genes in the analysis: (i) GWA-traits located in gene
exons and introns and in intergenic regions within 50 kb of the 5′
and 3′ regions of GTf-genes; and (ii) GWA-SNPs located in adjacent
genes within the 50 kb flanking regions was excluded. A total of
178 GWA traits were found for 80 GTf-genes, and these were
reported in 181 studies and associated with 269 SNPs (Figure 4 and
Supplementary data, Table SIV).
Overlaying the 80 GWAS candidate GTf-genes on the graphic
view of glycosylation pathways (Figure 1C), revealed that a small
majority (53/80) were classified as pathway-specific (Table I and
Figure 3A). Interestingly, the overlay pattern generated by GWA
GTf-genes resembled the pattern produced by GTf-genes classified
as regulated (Figure 1C), which looked like the mirror image of that
found for CDG GTf-genes. The majority of the GTf-genes impli-
cated by GWAS (64/80) were classified as being members of isoen-
zyme families (Figure 3B), and similarly the majority (55/80) found
to be classified as regulated (Figure 3C).
The comparison of GTf-genes underlying CDGs and implicated
by GWAS, illustrated by the heatmap in Figure 1C, clearly indicates
that these represent two quite distinct groups; however, there is a
significant overlap for 18 GTf-genes that have been found to cause
CDGs and are implicated by GWAS. The detailed analysis with
regards to classifications into pathway specificity, isoenzyme nature
and transcriptional regulation as summarized in Figure 3, further
revealed that the main differences between the two groups primarily
lies in the almost exclusive classification of CDGs to pathway-specific
glycosylation, whereas GWA GTf-genes are mainly associated with
isoenzyme families and dynamic transcriptional regulation.
GWAS implicate GTfs in diverse traits and
phenotypes
The 178 GWA-traits associated with the 80 GTf-genes represented a
large spectrum of predisposition traits spanning from common traits
such as low density lipoprotein and HDL cholesterol, triglycerides,
obesity (body mass index), bone mineral density (BMD), over to
neurological traits such as dementia, attention deficit hyperactivity
disorder, and schizophrenia, and finally to more general phenotypes
such as height and aging (Supplementary data, Table SIV). We
found SNP signal P-values less than 10−10 for 44 traits in 17 GTf-
genes, and SNP signal P-values less than 10−15 for 32 traits in 12
GTf-genes (Figure 4A). Among traits with the strongest SNP signals
were several recurrent traits mapped in different studies and with
multiple SNPs associating to the same GTf-gene. These include dysli-
pidemia traits for GALNT2, BMD trait for GALNT3, and body
height for COLGALT2 (Supplementary data, Table SIV).
We further inspected the genomic locations of SNPs and found
that a majority of the SNPs (60%) were intronic and half of these
were in the first intron of the GTf-genes, suggesting involvement of
regulatory regions (Figure 4B). A third of the SNPs were intergenic
and most of these located in the 5′ upstream 50 kb region. Very few
SNPs were in the 3′ UTRs and none in 5′ UTRs. As expected, few
SNPs were found in the coding regions of GTf-genes defining ABH
blood groups (Supplementary data, Table SV).
Discussion
The presented global analysis of the 167 human GTf-genes assign-
able to distinct glycosylation pathways demonstrates that genes
causing CDGs have distinct features from the group of genes impli-
cated by GWAS. CDG genes are characterized by primarily serving
pathway-specific roles in glycosylation, with a tendency to have
unique enzymatic functions and low transcriptional regulation. In
contrast, GWAS candidate genes are characterized by primarily
being members of paralogous gene families, where isoenzymes may
A
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Ex Ex
50kb50kb Intron
29 GTf genes; 55  SNPs 22 GTf genes; 30 SNPs
DownstreamUpstream
57 genes/155 SNPs
ivs1: 34 genes; 83 SNPs 
ivs2+: 39 genes; 72 SNPs
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3’ UTR
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Intergenic 33%
Intron 60%
5’ UTR
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17 genes
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Fig. 4. Summary of GWAS candidate GTf-genes included in the study. (A)
Graphic presentation of GWA-SNP p-values showing number of GTf-genes,
traits and SNPs reported with intervals of P < 10−5, P < 10−10 and P < 10−15.
(B) Graphic distribution of GWA-SNPs with respect to gene structure.
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provision for overlapping functions and differential transcriptional
regulation. The characteristic features of GTf-genes causing rare
CDGs were perhaps expected and consistent with their global effects
on glycosylation and often severe outcome (Freeze et al. 2014;
Jaeken and Péanne 2017). On the other hand, it may appear surpris-
ing that the many GTf-genes implicated by GWAS were found to be
rather distinct from the CDG groups. However, we clearly do not
have the complete picture and reports on new CDGs and GWA-
traits continue to appear. Moreover, a number of factors may bias
our current view including technical limitations in identifying subtle
nonglobal changes in the glycome and lack of understanding of non-
redundant functions of isoenzymes involved in glycosylation. Given
the large number of GTf-genes implicated by GWAS there is a clear
need to consider these and develop strategies for experimental valid-
ation, and the few examples validated to date seem to point to subtle
regulatory roles of glycosylation in more common diseases and
predispositions.
The current knowledge of CDGs caused by deficiencies in GTf-
genes is still incomplete (Freeze et al. 2014) and structural defects in
GTf-genes are extremely rare with allele frequencies of ≤0.001
(Hansen et al. 2015). While CDGs initially were discovered by, e.g.
analysis of the N-glycosylation state of plasma transferrin or charac-
teristic phenotypes associated with deficiencies in α-dystroglycan
glycosylation and GAG biosynthesis (Freeze et al. 2014), more
recent use of whole genome sequencing (WGS) or WES of patient
groups and consanguineous families are leading to the discoveries of
CDGs caused by GTf-genes that are members of isoenzyme families
with partially overlapping functions and only subtle nonglobal
imprints on the glycome (Freeze et al. 2014; and 2015). WGS and
WES strategies are not limited by the technical difficulties with find-
ing subtle changes in glycosylation perhaps restricted to certain
organs or even specific glycoproteins, yet once a potential CDG is
identified, it may be quite complex to identify the resulting glycosy-
lation changes and the molecular mechanisms underlying pheno-
typic characteristics. Recent examples are found among the
polypeptide GalNAc-transferase genes, where the phenotypic conse-
quences of complete deficiency are subtle and distinct due to loss of
O-glycosylation on one or only very few glycoproteins (Kato et al.
2006; Khetarpal et al. 2016). These findings are also reflected in the
many knockout (KO) studies of GTf-genes in mice and other animal
models (Lowe and Marth 2003; Stanley 2016). KO of GTf-genes
that result in early global elimination of specific glycosylation path-
ways generally lead to embryonic lethality, although this is not the
case with the GalNAc-transferase genes as there is substantial over-
lap in functions and only a limited number of proteins are affected
(Schjoldager et al. 2015; Khetarpal et al. 2016). KO of pathway-
specific GTf-genes acting later in the biosynthesis and without sub-
stantial redundancies in function generally produce postnatal severe
phenotypes (Stanley 2016). In contrast, KO of pathway-nonspecific
GTf-genes generally produce subtle or no apparent phenotypes, and
the targeted genes usually have substantial functional redundancy
from other isoenzymes.
Our analysis of GWAS implicated GTf-genes revealed, as pre-
dicted, that a significant number of these overlap with CDG GTf-
genes (Figure 1C). Moreover, in several cases the GWA traits are
consistent with the phenotypes associated with complete deficiency
in the corresponding CDGs (7/18). The best examples may be the
GalNAc-transferase genes GALNT2 and GALNT3. Loss of
GALNT3 causes hyperphosphatemia and ectopic ossifications and
the GWAS trait is bone mineral density (Topaz et al. 2004; Kato
et al. 2006; Estrada et al. 2012; Kemp et al. 2014), while loss of
GALNT2 results in low HDL and the GWAS trait indeed includes
low HDL (Willer et al. 2013; Khetarpal et al. 2016). In some cases,
the GWA traits may be related to phenotypes found in murine KO
models. Thus, GWA traits for MGAT5 include type 2 diabetes and
aging (Palmer et al. 2015; Pilling et al. 2016), and the Mgat5 KO
mice showed diminished glycemic response and increased insulin
sensitivity (Johswich et al. 2014) and accelerated aging (Dennis et al.
2002). The GWA traits for B3GNT2 include autoimmunity and
chronic inflammation (Okada et al. 2012, 2014), and the B3gnt2
KO mice showed hyperactivation of lymphocytes and enhanced ini-
tiation of immune responses by T cells and B cells (Togayachi et al.
2010). The GWA traits for B3GAT1 include verbal declarative
memory and schizophrenia (Debette et al. 2015; Goes et al. 2015),
and B3gat1 KO mice suffer from defects in higher brain functions
including special memory, leaning phenotypes and impaired synap-
tic plasticity (Yamamoto et al. 2002). In most cases though, the
murine KO phenotypes do not appear related to the identified GWA
traits.
The phenotypic correlations between loss of GTf-gene functions
in mice or man and GWAS candidate GTf-genes present one level of
validation of the GWAS candidates, and highlight that GTf-genes
are involved in highly specific and conserved glycosylation reactions
that impact common diseases. How this occurs is still unclear, but
as summarized in Figure 4 the location of the diagnostic SNPs for
most GWA traits are in nonexon regions and predicted to affect
transcriptional regulation. It is a general finding that GWA studies
point to regulatory parts of candidate genes suggesting that in most
cases the underlying mechanism for involvement in traits are allele-
specific transcription consequences (Maurano et al. 2012;
Lappalainen et al. 2013; Cavalli et al. 2016). As discussed above
this is clearly the case for the diagnostic SNPs identified for the HDL
trait in GALNT2. These are located in intron 1 close to a liver-
specific regulatory element, and they were demonstrated to produce
allele-specific transcript variations specifically in liver (Roman et al.
2015; Khetarpal et al. 2016). More examples are needed to confirm
if this is a common finding, but to explore the functional conse-
quence of such dysregulatory events, we will likely need to be able
to monitor quantitative changes in the glycosylation of specific gly-
coproteins derived from specific organs or cell types.
The finding that most GWAS candidate GTf-genes appear to be
members of larger isoenzyme gene families may not be surprising
(Figure 3B). Evolution of isoenzymes is a way to diversify and fine-
tune specific functions in addition to providing functional backup
for essential functions. This clearly applies to the many GTf-gene
families, where individual isoenzymes often are found to serve dis-
tinct functions, but with sufficient overlap in specificities to accom-
modate partial compensation. The crude analysis of transcriptional
regulation in human organs provided by others (Uhlén et al. 2015;
Petryszak et al. 2016) also pointed selectively to the GWAS candi-
date GTf-genes (Figure 3C), which suggests that differential and/or
tight regulation of these enzymes are important. An example illus-
trating this is again the GalNAc-T3 isoenzyme, which co-regulates
phosphate (Pi) homeostasis through specific nonredundant glycosy-
lation of FGF23 (Kato et al. 2006). Expression of GALNT3 as well
as FGF23 is tightly regulated (Chefetz et al. 2009; Ito et al. 2015),
and nonredundant GalNAc-T3 O-glycosylation of FGF23 fine-tunes
the biological function of FGF23 (Kato et al. 2006) essentially with-
out major biological effects on the many other proteins glycosylated
by this enzyme. It is still not clear how transcriptional regulation of
GTfs-genes can serve in fine-tuning highly specific and tightly regu-
lated processes.
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In summary, our global analysis of GTf-genes and diseases
draws attention to a group of glycosylation disorders caused by dys-
regulation rather than deficiency of GTfs. There are a number of
challenges in exploring these, and new strategies including single cell
transcriptomics and simple model systems for glycome analysis are
required. However, the results presented suggest that at least some
of the GWAS candidates are valid and play roles in more common
general traits and health conditions.
Materials and methods
Assembly of the human GTf-genome
The initial human GTf-gene list was retrieved from the GlyMAP list
of genes (Hansen et al. 2015), and updated using the recent Human
Reference Genome (GRCh38/hg38, NCBI, https://www.ncbi.nlm.
nih.gov) and CAZy database annotations (http://www.cazy.org/)
(Lombard et al. 2014). GTf genes with known function, but not
annotated in CAZy were curated from primary literature.
Classification of isoenzyme/nonisoenzyme and
collation of protein annotation data
An initial grouping of isoenzymes was based upon the CAZy GT-
family classification and was further refined by manual analysis and
literature search. For each GTf, the donor nucleotide, protein func-
tion, subcellular localization and protein type was curated from
CAZy, UniProt (http://www.uniprot.org/) and primary literature.
Signal peptides and transmembrane spanning domains were anno-
tated using the prediction servers SignalP (http://www.cbs.dtu.dk/
services/SignalP/) and TMHMM (http://www.cbs.dtu.dk/services/
TMHMM/), respectively.
Compilation of CDG data
The assembly of the CDGs caused by GTf-genes was built upon
recent summarizing reviews (Freeze et al. 2014; 2015; Jaeken and
Péanne 2017), supplemented with data from OMIM (https://omim.
org/) and the Human Genome Mutation Database (HGMD) (http://
www.hgmd.cf.ac.uk/).
Analysis of transcriptome information
The transcriptomic dataset for analysis was chosen from amongst
the datasets available on Expression Atlas (Petryszak et al. 2016)
(https://www.ebi.ac.uk/gxa/), selecting for a dataset that had a rea-
sonable number of tissues included. Consequently, the transcrip-
tomic data from the HPA (Uhlén et al. 2015) was chosen for further
analysis. The RNAseq data comprises a map of gene expression in
32 different human tissues (Supplementary data, Table SVI)
obtained from 122 healthy individuals. Since we only needed access
to summarized data across different individuals, mean TPM
(Transcripts Per Million) values per tissue were retrieved from the
Expression Atlas in CSV format.
As a heuristic for evidence of tissue-specific gene regulation, we
chose to use the dimensionless Tau (τ) value (Yanai et al. 2005), a
metric that performs generally well with respect to measuring tissue-
specific expression (Kryuchkova-Mostacci and Robinson-Rechavi
2017). τ-values were calculated in R for each of the GTf-genes
across the 32 tissue samples. In order to choose a cutoff τ-value to
distinguish between regulated and nonregulated, we modeled the
τ-value distribution for all GTF-genes as a two component mixed
Gaussian model. The model comprises a component with mean at τ
0.55 (not-regulated) and another with mean at τ 0.86 (regulated).
The intersection of the component curves at τ 0.71 can be used as a
cutoff point. τ values greater than this cutoff represent regulated,
and lower than this value represent not-regulated (Supplementary
data, Figure S2). This is clearly a crude estimation, but given that
current RNAseq data is derived from complex tissues and not dis-
tinct cell types, we do not believe more detailed analysis is war-
ranted. Adapted from the HPA, levels for TPM < 1 represent no
detection of reads, TPM∈[1–10] represent low expression,
TPM∈[10–50] represent medium expression and TPM > 50 high
expression.
Compilation of GWAS data
The GWAS data analysis was based on data from the GWAS
Catalog (download October 2017, https://www.ebi.ac.uk/gwas/),
which is a manually curated literature-driven collection of published
GWA Studies representing SNP-traits with a statistical significance
of P-values < 1 × 10−5 (MacArthur et al. 2017). From the initial
dataset retrieved from the GWAS Catalog, the data was filtered set-
ting inclusion criteria for GWA-SNPs to be localization in GTf-gene
exons, introns or flanking intergenic 50 kb regions. SNPs located
within adjacent genes in the 50 kb flanking regions were excluded
from further analysis. SNPs were analyzed for genomic localization
in exons, UTRs, introns and intergenic regions using the longest
RefSeq transcript. The GWAS catalog disease/trait associations
terms were adapted for the GWA-GTf analysis and are cataloged in
Supplementary data Table SIV including GWA GTf-genes, SNP id,
P-value intervals and GWAS references.
Internet resources
CAZy, the Carbohydrate-Active enZYmes Database (http://www.
cazy.org/)
CBS Prediction Servers (http://www.cbs.dtu.dk/services/)
EMBL-EBI Expression Atlas (https://www.ebi.ac.uk/gxa/home)
Ensembl (http://www.ensembl.org/)
NCBI (https://www.ncbi.nlm.nih.gov)
GWAS Catalog (https://www.ebi.ac.uk/gwas/)
HGMD, Human Genome Mutation Database Cardiff (http://www.
hgmd.cf.ac.uk/)
Human Protein Atlas, HPA (https://www.proteinatlas.org/)
OMIM (https://omim.org/)
SignalP (http://www.cbs.dtu.dk/services/SignalP/)
TMHMM (http://www.cbs.dtu.dk/services/TMHMM/)
UniProt (http://www.uniprot.org/)
Supplementary data
Supplementary data is available at GLYCOBIOLOGY online.
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